<DOC>
	<DOC>NCT02105168</DOC>
	<brief_summary>Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of why those patients are relapsing using next generation sequencing to identify rare mutations and assessed their predictive value.</brief_summary>
	<brief_title>Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>1. Cytological or histological diagnosis of SCLC, NSCLC or melanoma 2. Patients age &gt;/= 18 years old 3. Indication of treatment using platinum salts for lung cancer except for patient with NSCLC treated by surgery for whom platinum salts is not indicated 4. If a biopsy is proposed, lesion lust be easily accessible 5. Signed informed consent 1. Patients unable to follow the protocol 2. Consent refusal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>